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discouraged from joining by others (p<.001), not having an intrin- 
sic commitment to donate (p<.001), feeling encouraged by ones' 
culture or religion to join (p<.05), feeling like there are risks to 
donat ion (p<.01), and having a greater number  of medical 
(p<.001), and work and family concerns (p<.05) about donation - -  
were uniquely associated with higher levels of ambivalence after 
adjusting for the effects of other key indicators. We can conclude 
from these findings, that potential donors who are nmtivated by 
an intrinsic connnitment to donate, rather than extrinsic pressure, 
are less ambivalent about donating. In addition, recrnitment staff 
have a potentially critical role in reducing ambivalence among 
new recruits by providing information that may allay any unrealis- 
tic concerns recruits may have about the medical risks, and the 
impact of donation on work and family commitments. 
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T-CELL DEPLETED ALLOGENEIC BONE MARROW TRANSPLANTATION 
FOLLOWED BY T CELL ADD-BACK IN PATIENTS WITH MULTIPLE 
MYELOMA 
Magalhaes-SilveJvna~l, M.; Lee, C.; Hohl, R.; Ritehie, J.; GiJzgrich, R. 
Interval MedMTze, University of Iowa, Iowa City, L~I. 
Allogeneic haematopoietic transplantation is potentially curative 
for patients (pts) with multiple myeloma. However, a high treat- 
ment-related mortality contributes to poor overall survival.An allo- 
geneic graft-versus-myeloma effect mediated by donor lymphocyte 
infusions has been demonstrated. Measures to minimize TRM while 
maintaining a graft-versus-host myeloma are needed.We valuated 
the outcome of 21 patients (pts) treated with a conditioning regimen 
comprising TBI  (1200cGY) ,  BCNU (300mg/m2), etoposide 
(1200rag/m2), ARA-C (6gin/m-') and cyclophosphamide (90mg/Kg) 
followed by T cell depleted bone marrow transplantation. Donor T 
cells were infused after transplantation ver a period of 2-3 months if 
acute GVHD gradec~ II was not seen. Cyclosporin was used for 
GVHD prophylaxis. Ten pts underwent transplantation using a sib- 
ling donor while 11 had an unrelated onor. There were 21 pts with 
a median age of 52 years (range 42-56); 14 were male and 7 female; 
median time from diagaaosis to transplantation was 16 months (range 
5-60); at diagnosis all pts had stage III disease; Ig type was igG in in 
12 pts, IgA in 5 and light chain in 4. Seventeen pts had sensitive dis- 
ease at time of transplantation. Twenty pts survived more than 21 
days and are evaluable for engraftment. The  median time to 
ANCc<0.5xl09/g was 14 days (range 12-30) and to a 
plateletc~25x10Q/L was 29 (range 12-70). Five pts died before day 
100. Cox proportional hazards models were used to identify factors 
associated with disease-free (DFS) and overall survival (OS). The risk 
factors considered : type of transplant( related vs unrelated), age ( 
<_50 vs~50), acute GVHD, chronic GVHD, disease sensitivity, gen- 
der, immunoglobulin type and T cell add-back. Univariate analysis 
demonstrated that gender (p=0.046) and T cell add-back (p=0.008) 
were predictive of OS. Type of transplant (p=0.047) and T cell add- 
back (p=0.005) were predictive of DFS. In a multivariate model type 
of transplant and T cell add-back were significantly associated with 
OS and DFS. The two year estimated OS and DFS for pts receiving 
T cell add-back is 50% and 40% respectively and for those not 
receiving T cell add-back is 9% and 0%. Our study demonstrates 
that T cell add-back after allogeneic T ceil depleted bone marrow 
transplantation induces ignificant graft-versus-myeloma effect. 
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Between August 1990 and June 2002, 25 patients with MF due 
to AMM (n=19) or ET  (n=6) underwent al loBMT at PMH or 
VGH.  The  median age at transplant was 48.7 ( Interquart i le 
range(IQR) 45.9-50.4) years, 18/25 were male and Lille risk 
groups at diagnosis were low (n=3), intermediate (n=13) and high 
(n=9) at diagnosis. Cytogenetics were abnormal in 8/19 cases test 
ed. Seven patients had previously undergone splenectomy and 
none of the patients had received induction therapy for leukemic 
transformation. Transplants took place a median of 10.7 (IQR 
5.67-26.5) months after diagnosis and median follow-up of surviv 
ing patients is 35 (IQR 21-61) months. Conditioning regimens 
were Cy/TBI (n=23) or Bu/Cy-2 (n=2), and all received CyA-Mtx 
for GVI ID  prophylaxis. Donors were matched (n=13) or mis- 
matched (n=2) relatives or matched unrelated volunteers (n=10). 
The median cell dose was 2.8 (IQR 1.88-3.78) xl0A8 MNC/kg. 
ANC > 500/btL and platelets > 20, 000/btL were observed in 22/22 
(median 25d.) and 17/22 (median 35d.) evaluable patients, respec- 
tively; median time to last RBC transfusion was 123 day's. Prior 
splenectomy was associated with more rapid neutrophil recovery 
(20 vs. 27.5 days, p=0.0019). Primary graft failure occurred in two 
cases, but both patients successfi~lly engrafted with a second trans- 
plant. Hepatic VOD occurred in 10 cases. Acute GVHD was 
grade II-IV in 13 and III IV in 4 cases. Chronic GVHD occurred 
in 10/17 evaluable patients. Eighteen patients had at least one 
bone marrow biopsy after transplantation. Median time to free- 
dora from fibrosis was 363d; at 18 months 84% of patients were 
free of fibrosis. A complete remission (defined as normalization of 
blood counts and absence of fibrosis and splenomegaly) occurred 
in 6 and CRP(as for CR with platelet count below normal) in 2 of 
18 cases with repeat biopsies. Median survival was 13.1 (IQR 3.6- 
33.8) months from BMT, 49.8 (IQR 17-66) months from diagno- 
sis. Kaplan-Meier estimate of 18-month overall survival was 
48.4%. Secondary engraftment failure occurred in one patient 
who died of GVHD on day 109. Non-re lapse mortal ity was 
observed in 10 cases and 4 patients died of progressive disease. We 
conclude that alloBMT offers a reasonable chance for resolution 
of MF, and may result in long-term disease-free survival. 
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Sal, lofl~ M.S ; 3/lcDiar'mid, S/ ; Be~zce-Bruckler, I /  ; Atkins, H.2; Bredes- 
ou, C.s; Hopkins, H.Z; Genest, P.~-; Pe*'vy, G.2; Huebsch, b.lg. 1 
1. Ottawa Hospital, Ottawa, ON, CaTlada; 2. Ottawa Regio*~al Ca*lcer 
Cemre, Ottawa, ON, Canada, 3. Medical College of ~/iscousin, Mil- 
waukee, ~1~7. 
Allogeneic hematopoietic stem cell transplants (al lo-HSCT) 
have a number  of potent ia l  advantages over an autologous 
henaatopoietic stem cell transplant (AHSCT) in the treatment of 
follicular lymphoma (FL). We analyzed our experience in allo- 
HSCT for FL after establishing a program at our institution, 10 
years ago. Between April 1992 and September 1999, 19 patients 
with FL underwent an allo-HSCT. The median age was 41.7 (29- 
55) years. 8/19 were male. The  original diagnosis was FSCL 
(10/19), FML (4/19), FLCL (2/19) and 3/19 were transformed. 
5/10 had a previous AHSCT.  6/19 had received 1 pr ior 
chemotherapy, 9/19 had received 2 prior chemotherapies and 4/19 
had received >2 prior chemotherapies. 5/19 had received a prior 
AHSCT. 17/19 were transplanted from a related donor and 2 of 
these were syngeneic pairs. 13/17 who had a related donor 
received a CD34-selected marrow. The 2 syngeneic transplants 
used either unmanipulated marrow or PBSC. The remaining 2 
related al lo-HSCT received umnanipulated marrow. The condi- 
t ioning regimen in 14/19 was VP-16 (60 
mg/kg)/melphalan(14Omg/m2)/TBI(500 [13/19] or 1200 
[l/19]cGy). The remainder eceived BU/CY (4/19) or CY/TBI 
(1/!9). 12/19 received 1.25 mg/kg ATG. 13/19 received only 
cyclosporin for GVHD prophylaxis while 4/19 received bot[a 
cyclosporin and methotrexate and no GVHD prophylaxis was 
given to the syngeneic recipients. The  median follow-up and 
range has been 4.3 (0 - 8.9) years. The median time and range to 
neutrophil (>0.5x109/L) and platelet (>20x109/L) engraftment 
was 17 (11 - 30) and 22 (8 168) days, respectively. Acute GVHD 
was seen in 4/19 patients. 3/4 had grade 2 - 3 GVHD. 5/19 had 
chronic GVHD. 5/19 developed CMV detected in the blood and 
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